Food and Behaviour Research

Donate Log In

Choline - A Neglected Nutrient Vital for Healthy Brains - BOOK HERE

Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study.

Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, Mischoulon D (2015) Mol Psychiatry.   doi: 10.1038/mp.2015.22. [Epub ahead of print] Nature Publishing Group

Web URL: Read more and find related articles on the pubmed website here


This study explores whether inflammatory biomarkers act as moderators of clinical response to omega-3 (n-3) fatty acids in subjects with major depressive disorder

One hundred fifty-five subjects with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) MDD, a baseline 17-item Hamilton Depression Rating Scale (HAM-D-17) score ⩾15 and baseline 
biomarker data (interleukin (IL)-1ra, IL-6, high-sensitivity C-reactive protein (hs-CRP), leptin and adiponectin) were randomized between 18 May 2006 and 30 June 2011 to 8 weeks of double-blind treatment with eicosapentaenoic acid (EPA)-enriched n-3 1060 mg day-1, docosahexaenoic acid (DHA)-enriched n-3 900 mg day-1 or placebo.

Outcomes were determined using mixed model repeated measures analysis for 'high' and 'low' 
inflammation groups based on individual and combined biomarkers.
Results are presented in terms of standardized treatment effect size (ES) for change in HAM-D-17 from baseline to treatment week 8.

Although overall treatment group differences were negligible (ES=-0.13 to +0.04), subjects with any 'high' 
inflammation improved more on EPA than placebo (ES=-0.39) or DHA (ES=-0.60) and less on DHA than placebo (ES=+0.21); furthermore, EPA-placebo separation increased with increasing numbers of markers of high inflammation.
Subjects randomized to EPA with 'high' IL-1ra or hs-CRP or low adiponectin ('high' 
inflammation) had medium ES decreases in HAM-D-17 scores vs subjects 'low' on these biomarkers.
Subjects with 'high' hs-CRP, IL-6 or leptin were less placebo-responsive than subjects with low levels of these biomarkers (medium to large ES differences).
Employing multiple markers of 
inflammation facilitated identification of a more homogeneous cohort of subjects with MDD responding to EPA vs placebo in our cohort.

Studies are needed to replicate and extend this 
proof-of-concept work.